Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. - Wikidata - awgldk - TriplyDB

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

http://www.wikidata.org/entity/Q54374929

about

Cancer-Specific Telomerase Reverse Transcriptase (TERT) Promoter Mutations: Biological and Clinical Implications Transcription Regulation of the Human Telomerase Reverse Transcriptase (hTERT) Gene Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.Towards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel.TERT promoter mutations and gene amplification: promoting TERT expression in Merkel cell carcinoma Telomere-regulating genes and the telomere interactome in familial cancers.Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms.A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERT TERT promoter mutations and telomere length in adult malignant gliomas and recurrences.High nevus counts confer a favorable prognosis in melanoma patients.Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis.Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression In the Wnt-er of life: Wnt signalling in melanoma and ageing.Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.Association of TERT promoter mutations with telomerase expression in melanoma.Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies.Genetic and Epigenetic Alterations of TERT Are Associated with Inferior Outcome in Adolescent and Young Adult Patients with Melanoma.Telomerase promoter mutations in cancer: an emerging molecular biomarker?Understanding TERT Promoter Mutations: A Common Path to Immortality.Differential diagnosis of Spitzoid melanocytic neoplasms.Altered TERT promoter and other genomic regulatory elements: occurrence and impact.In-situ hybridization-based quantification of hTR: a possible biomarker in malignant melanoma.TERT promoter mutations in melanoma survival.Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.Distribution of TERT promoter mutations in primary and metastatic melanomas in Austrian patients.Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.Mapping of deletion breakpoints at the CDKN2A locus in melanoma: detection of MTAP-ANRIL fusion transcripts.TERT promoter mutations in melanoma render TERT expression dependent on MAPK pathway activation.Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma.TERT promoter mutations are not always associated with poor prognosis in atypical spitzoid tumors.ETS1, nucleolar and non-nucleolar TERT expression in nevus to melanoma progression.Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma.Intratumoral heterogeneity and TERT promoter mutations in progressive/higher-grade meningiomas.TERT promoter mutations associate with MC1R variants in melanoma patients.Regulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer.Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.

P2860

Q26738705-0AB3757E-FFEF-439A-A0AE-C2D19282FC54 Q26739925-95E5B4D6-34E1-4D82-A6CB-AD23578E22C0 Q30459452-9469446E-56C2-405C-A324-F10E3D6E0F3E Q33674041-B47C1D37-053D-4D63-BFA8-E32CB088DCBA Q34654382-244383AE-6640-4A35-ACAD-51E424FC893E Q34784471-1562286A-1F7A-411C-A364-F4615E3326EB Q35176032-ADA4492E-17CC-424E-A27B-ED1A3A44D0A1 Q35711083-95ED9619-CFC4-47B5-AD41-1772020921BA Q35751775-840352BF-3830-495C-8223-59790895D10D Q35833084-4571C06F-A1EA-49E4-AE6E-21A9F51F0A3C Q35855182-06A8CE67-340E-4FEA-BAA3-58726E22845B Q35901458-95064CB5-32CC-4B86-9F18-698683E4AF73 Q36635311-F519ED9B-6F03-4BEC-830E-32A29F858BC2 Q36729504-299B5310-EB8E-42DC-9D0A-B3F8F74CA368 Q37395716-9F01E490-3EE9-4A95-AAFE-ACB6C31E9519 Q37457229-BD30F80C-5983-447F-98A8-427098D8A486 Q37514988-D19A0803-241F-4762-86C3-56FE5BAB68B7 Q37596033-2EE9C2AB-CFAB-4673-B878-1D2AFE58691B Q37596836-D0B87591-80A5-4FCC-A738-648E3294EF40 Q37687028-879E07B9-6203-40A8-8454-5939757F28A3 Q37738007-B66814F7-D9D5-4C25-9AC9-0F57B55053B5 Q38232447-E80A9894-CFA9-482F-917E-4F9DA8E5C325 Q38760235-C4F370B8-D097-41F3-9B83-6238E2A37691 Q38833186-DC458CFF-0FEF-43FD-A5E1-1AB79B0AB193 Q38838144-3F2F9E01-6442-43AD-AC62-3FDC3848C002 Q39053783-FB82020A-BB74-475B-83A4-47FBD928876E Q39998496-2567B965-F7C2-497A-BCD5-184C7427397C Q40085142-43559A0B-1963-485A-84F1-56EF29929E2C Q40418885-66E1823D-6E5C-405E-8B38-4B7759CFE308 Q40857012-CB08441D-4653-4B95-B0E7-178F10C4A7C8 Q40891138-F371640B-47B4-4E28-8332-1B3A3A5D71A5 Q42324664-23F2FD99-ED25-46BA-BD15-6AE2FE4FF5D2 Q43274590-C26D447F-1E83-484D-B65B-EEE49E76A480 Q45295435-D02DEF12-D104-4703-8E5C-61A65937DAA8 Q47224965-4124AB5B-1C8F-48CD-B90F-A63CADF0ECD4 Q47418685-2B05F1AD-03A5-4CC9-8171-083541C39F3A Q47745006-B031E5C3-E591-429C-AAE3-8C7B98F8E42D Q48174015-F05D930D-346E-48AF-9CA9-34C695808E60 Q49358253-256122BB-CCAD-47D1-BF95-E5C4D68A7EAC Q49787884-9D6DA84D-CB21-40A3-8086-308CDA0AC1CD

P2860

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

http://www.wikidata.org/entity/Q54374929

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

@en

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

@nl

type

label

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

@en

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

@nl

prefLabel

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

@en

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

@nl

P1433

Q54374929-675AB034-6CF1-4F70-B62B-6C42A569412B

P1476

Q54374929-B8B09D27-67A0-4545-87BA-B1217D43404A

P2093

Q54374929-4BA22552-ABA8-4DA5-AC12-584C31E8660B

Q54374929-68FE0EBA-C5AB-40FC-8A70-E6F0F0EB4E3C

Q54374929-848F7E04-F9FC-451F-B1A5-18189142D574

Q54374929-86BDD0F2-41AE-4C9F-8D90-575899F882DF

Q54374929-9D4892A4-94C5-4176-8DE6-C901A4F14105

Q54374929-A4E67915-1052-452C-90C0-4B1351F576CA

Q54374929-F01B4E61-317D-457F-AD1B-96B1C26438E7

P2860

Q54374929-04D9E30A-8DF2-49C0-90E8-4ABF090B699C

Q54374929-08FE51FD-610C-424D-AC6A-49D833EAB6CB

Q54374929-1803DDE3-A9B3-4598-8DB5-AE21717880C2

Q54374929-1BF613A9-6FFE-49D8-A893-7930C2FF5C20

Q54374929-257131B1-1357-4AC6-ABAD-9CDB54166CD1

Q54374929-2DEB9364-7188-44DC-B688-BDB64B85597C

Q54374929-2F9B6859-D2C7-40EA-AFED-E145845AAD62

Q54374929-436C8A11-FA87-4DCC-B9DD-C0A954FCE059

Q54374929-460C62CF-5FC1-4943-8B48-B26906CDB659

Q54374929-5FAF212B-31BF-4191-83AC-BBE8909DDB76

P2888

Q54374929-E7B0BB10-85C2-460A-9654-62FD38212BA3

P304

Q54374929-514011EE-62F8-4AEB-836A-1AB02564C324

P31

Q54374929-D998E790-C70B-4726-926C-3004AA3D2C4F

P356

Q54374929-EC9611EC-6337-4417-BAD5-9F2707F239FC

P407

Q54374929-F49B17AB-ED16-4E46-8778-F652B22AC39F

P478

Q54374929-8C8002F2-7DEA-46CD-BE84-3B3D320F5330

P50

Q54374929-28CEE906-88D8-47A3-9B1F-9369EF174823

Q54374929-42784A21-BAC4-43D5-B731-B2F845A5A3ED

Q54374929-982E1BFC-2A57-4BD8-9660-A97FFE4C19EA

P577

Q54374929-6EA9232F-4BA9-45B5-9E39-A3F0CA008F84

P5875

Q54374929-6BA8926D-CD3F-4456-A980-241EED54C457

P698

Q54374929-2FA96169-FA64-4780-9D1F-02D2D720D154

P356

P1433

Nature Communications

P1476

Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma.

@en

P2093

Barbara Heidenreich

http://www.w3.org/2001/XMLSchema#string

Celia Requena

http://www.w3.org/2001/XMLSchema#string

Jürgen Becker

http://www.w3.org/2001/XMLSchema#string

Nadem Soufir

http://www.w3.org/2001/XMLSchema#string

P Sivaramakrishna Rachakonda

http://www.w3.org/2001/XMLSchema#string

Victor Traves

http://www.w3.org/2001/XMLSchema#string

Zaida Garcia-Casado

http://www.w3.org/2001/XMLSchema#string

P2860

A landscape of driver mutations in melanoma

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

JASPAR, the open access database of transcription factor-binding profiles: new content and tools in the 2008 update

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.

Determinants of BRAF mutations in primary melanomas

Signatures of mutational processes in human cancer

Highly recurrent TERT promoter mutations in human melanoma

TERT promoter mutations in familial and sporadic melanoma

Telomere biology and translational research.

Telomere rejuvenation during nuclear reprogramming.

P2888

P304

3401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCOMMS4401

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260380807

http://www.w3.org/2001/XMLSchema#string

P698

24569790

http://www.w3.org/2001/XMLSchema#string